Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
IPO Year:
Exchange: NASDAQ
Website: brightmindsbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/13/2025 | Buy | TD Cowen | |
| 5/7/2025 | $80.00 | Buy | Chardan Capital Markets |
| 1/23/2025 | $93.00 | Overweight | Piper Sandler |
| 1/10/2025 | Overweight | Cantor Fitzgerald | |
| 1/10/2025 | $85.00 | Buy | H.C. Wainwright |
| 11/26/2024 | $75.00 | Outperform | Robert W. Baird |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
3 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)
F-3 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)
SCHEDULE 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
TD Cowen initiated coverage of Bright Minds Biosciences with a rating of Buy
Chardan Capital Markets initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $80.00
Piper Sandler initiated coverage of Bright Minds Biosciences with a rating of Overweight and set a new price target of $93.00
Cantor Fitzgerald initiated coverage of Bright Minds Biosciences with a rating of Overweight
H.C. Wainwright initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $85.00
Robert W. Baird initiated coverage of Bright Minds Biosciences with a rating of Outperform and set a new price target of $75.00
Fastest customizable press release news feed in the world
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT: 36th International Epilepsy Congress, Lisboa Congress Centre, Lisbon, PortugalDATE: August 30 – September 3, 2025 EVENT: Cantor Global Healthcare Conference 2025DATE:Friday, September 5, 2025TIME:9:45am ETWEBCAST: https://stream.onstreammedia.com/onsm/GetReport?customerId=22&eventId=3773715
NEW YORK and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and Jan Torleif Pedersen, Chief Scientific Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows: Date:Thursday, June 5, 2025 Time:8:10m ET Webcast:Click Here To schedule a 1x1 meeting with the Company, please contact your Jefferies represe
- Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D'Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD - VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced the featured speakers for its virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am – 11:30 am ET. The KOLs will provide an overview of Absence epilepsy and syndromes, highlighting the burden of Abse
- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - - Findings highlight BMB-101's potential to address critical gaps in SUDEP prevention - NEW YORK and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced positive findings from its DBA/2 mouse model study. BMB-101, the Compan
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am – 11:30 am ET. The event will provide an overview of absence seizures and will focus on the unmet need in this group of epilepsy patients. The webcast will include presentations from renowned Key Opinion Leaders (KOLs) in epilepsy research, as well as an overview of the Company'
– Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug development and research to support Company's clinical focus on epilepsy – VANCOUVER, British Columbia, March 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced the expansion of its Scientific Advisory Board (SAB) to include five distinguished experts in epi
NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and select members of senior management, will participate in three healthcare conferences, as follows: TD Cowen 45th Annual Health Care Conference, Boston Monday, March 3, 2025, at 1:10pm ETJoin the webcast Leerink Partners Global Healthcare Conference, MiamiWednesday, March 12, 2025 (1x1
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an
- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, is proud to announce two upcoming presentations at the American Epilepsy Society 2024 Annual Meeting in Los Angeles, December 6-10, 2024. The Company's presentation details are as follows: Title: Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company ("Shares") at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 (the "Offering"). The Company is pleased to announce that the Offering included participation from Cormorant Asset Management, RA Capital Management, Perceptive Advisors, Janus Henderson Investors, Vivo Capital, Acuta Capital Partners, Schonfeld Strategic Advisors, and other
This live feed shows all institutional transactions in real time.
SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13D/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13D/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)
Live finance-specific insights
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas, Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor, and other key speakers will host a symposium on the recent therapeutic developments within the Dravet Syndrome landscape.
Live Leadership Updates
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an
-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 -- VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for a
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds Board. "In his short tenure on the Board, Doug's scientific, clinical, and medical experience has proven invaluable in supporting our efforts to develop the next generation of safe and efficacious drugs for challenging br
-- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system ("CNS") clinical development expertise -- VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Mark A. Smith M.D., Ph.D. will join the Company as Chief Medical Officer, effective December 1, 2022. The Company also announces that Dr. Revati Shreeniwas' engagement with Bright Minds as Chief Medical Officer has been terminated. "I'm thrilled
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the appointment of Doug Williamson to the Company's Board of Directors (the "Board"). Dr. Williamson will serve on the Compensation, Nominating and Corporate Governance, and Audit Committees as an independent